Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of intravenous TAK-341 in multiple system atrophy
jRCT2011220029Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of MEDI1341 in multiple system atrophy (MSA) (4 cohorts), sponsored by Takeda. Primary endpoint: Change from Baseline in modified UMSARS Part I Total Score at Week 52. Started Nov 2022; status: completed.
02
Drugs
MEDI1341
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on jRCT2011220029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220029.